# Emerging Neurobiological and Therapeutic Insights into Schizophrenia: A Comprehensive Review

**Authors:** Anamaria Oatu, Tudor-Florentin Capatina, Iulia-Cristina Mandras, Antonia-Lucia Comsa, Simona Trifu, Arina-Cipriana Pietreanu

PMC · DOI: 10.3390/ijms27041906 · 2026-02-16

## TL;DR

This review explores new biological insights and treatment approaches for schizophrenia, emphasizing the need for integrated and personalized care.

## Contribution

The paper provides a comprehensive synthesis of emerging neurobiological mechanisms and treatment guidelines for schizophrenia.

## Key findings

- Neuroinflammation, oxidative stress, and gut-brain interactions are emerging as key mechanisms in schizophrenia.
- Second-generation antipsychotics are widely recommended as first-line therapy, with clozapine for treatment-resistant cases.
- Integrated psychosocial interventions are emphasized across guidelines to improve long-term outcomes.

## Abstract

Schizophrenia is a complex, chronic psychiatric disorder with significant global impact, characterized by persistent positive, negative, and cognitive symptoms that are not fully addressed by current treatments. This review aims to synthesize established theories and advancing mechanistic concepts and also critically compare the latest international treatment guidelines. Recent evidence expands beyond the traditional dopamine hypothesis to include glutamatergic, serotonergic, and cholinergic dysfunctions, as well as emerging mechanisms such as neuroinflammation, oxidative stress, iron dysregulation, and gut–brain interactions. A review of major international guidelines (APA, NICE, CINP, WFSBP, and others) confirms consensus on the use of second-generation antipsychotics as first-line therapy and the early introduction of clozapine for treatment-resistant cases. All guidelines emphasize the essential role of integrated psychosocial interventions, including cognitive behavioral therapy for psychosis, family psychoeducation, and supported employment. Differences remain regarding the prioritization of precision medicine, pharmacogenomics, and digital health innovations. Prognosis varies widely but improves with early intervention, sustained treatment adherence, and comprehensive physical health monitoring. Overall, schizophrenia care is evolving toward a precision-based, recovery-oriented model that integrates biological, psychological, and social strategies to improve long-term outcomes and quality of life.

## Linked entities

- **Diseases:** schizophrenia (MONDO:0005090)

## Full-text entities

- **Genes:** PRL (prolactin) [NCBI Gene 5617] {aka GHA1, pPRL}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, GAD2 (glutamate decarboxylase 2) [NCBI Gene 2572] {aka GAD65}, CHRNA4 (cholinergic receptor nicotinic alpha 4 subunit) [NCBI Gene 1137] {aka BFNC, EBN, EBN1, NACHR, NACHRA4, NACRA4}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, Grin1 (glutamate receptor, ionotropic, NMDA1 (zeta 1)) [NCBI Gene 14810] {aka GluN1, GluRdelta1, GluRzeta1, M100174, NMD-R1, NMDAR1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, NR3C1 (nuclear receptor subfamily 3 group C member 1) [NCBI Gene 2908] {aka GCCR, GCR, GCRST, GR, GRL}, CYP2D6 (cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)) [NCBI Gene 1565] {aka CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, GNAQ (G protein subunit alpha q) [NCBI Gene 2776] {aka CMAL, G-ALPHA-q, GAQ, SWS}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, DRD2 (dopamine receptor D2) [NCBI Gene 1813] {aka D2DR, D2R}, TAAR1 (trace amine associated receptor 1) [NCBI Gene 134864] {aka TA1, TAR1, TRAR1}, ENPEP (glutamyl aminopeptidase) [NCBI Gene 2028] {aka APA, CD249, gp160}, NUP43 (nucleoporin 43) [NCBI Gene 348995] {aka bA350J20.1, p42}, NRG1 (neuregulin 1) [NCBI Gene 3084] {aka ARIA, GGF, GGF2, HGL, HRG, HRG1}, Pvalb (parvalbumin) [NCBI Gene 19293] {aka PV, Parv, Pva}, FOSB (FosB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2354] {aka AP-1, G0S3, GOS3, GOSB}, HTR2A (5-hydroxytryptamine receptor 2A) [NCBI Gene 3356] {aka 5-HT2A, HTR2}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, HTR1A (5-hydroxytryptamine receptor 1A) [NCBI Gene 3350] {aka 5-HT-1A, 5-HT1A, 5HT1a, ADRB2RL1, ADRBRL1, G-21}, CYP1A2 (cytochrome P450 family 1 subfamily A member 2) [NCBI Gene 1544] {aka CP12, CYPIA2, P3-450, P450(PA)}, CYP2C19 (cytochrome P450 family 2 subfamily C member 19) [NCBI Gene 1557] {aka CPCJ, CYP2C, CYPIIC17, CYPIIC19, P450C2C, P450IIC19}
- **Diseases:** tardive dyskinesia (MESH:D004409), depressive symptoms (MESH:D003866), oligodendrocyte dysfunction (MESH:D056784), weight gain (MESH:D015430), aggression (MESH:D010554), myocarditis (MESH:D009205), GABAergic dysfunction (MESH:D006331), constipation (MESH:D003248), hyperprolactinemia (MESH:D006966), cognitive symptom (MESH:D019954), functional disability (MESH:D003291), substance misuse (MESH:D009293), QT interval prolongation (MESH:D008133), neurodevelopmental disorder (MESH:D002658), Hyperactive (MESH:D006948), glutamatergic dysregulation (MESH:D021081), major depressive disorder (MESH:D003865), motivational deficits (MESH:D009461), immune dysregulation (OMIM:614878), blunted affect (MESH:D014949), iron (MESH:D000090463), memory deficits (MESH:D008569), CBTp (MESH:D003072), dopaminergic (MESH:D009422), disorder (MESH:D009358), cholinergic (MESH:C535672), disability (MESH:D009069), EPS (MESH:D001480), symptoms (MESH:D012816), dopaminergic abnormalities (MESH:D009421), auditory verbal hallucinations (MESH:D006212), cardiometabolic disorders (MESH:D024821), neurotransmitter abnormalities (MESH:D000014), injury to (MESH:D014947), Disease (MESH:D004194), agranulocytosis (MESH:D000380), inflammatory (MESH:D007249), Metabolic complications (MESH:D020739), congenital malformation (OMIM:163000), TRS (MESH:D000090663), pain (MESH:D010146), anhedonia (MESH:D059445), deaths (MESH:D003643), delusions (MESH:D063726), neuropsychiatric syndrome (MESH:C000631768), immune (MESH:D007154), DUP (MESH:D011618), NMDAR hypofunction (MESH:D060426), cortical and subcortical dysfunction (MESH:D002544), Alzheimer's disease (MESH:D000544), behavioral dyscontrol (MESH:D001523), SUDs (MESH:D019966), neuroinflammation (MESH:D000090862), Schizophrenia (MESH:D012559), akathisia (MESH:D017109)
- **Chemicals:** metformin (MESH:D008687), [18F]-DOPA (MESH:C043437), chlorpromazine (MESH:D002746), ulotaront (MESH:C000705647), fluphenazine (MESH:D005476), perphenazine (MESH:D010546), Acetylcholine (MESH:D000109), LPS (MESH:D008070), LSD (MESH:D008238), lipid (MESH:D008055), iron (MESH:D007501), minocycline (MESH:D008911), aripiprazole lauroxil (MESH:C000603935), Xanomeline (MESH:C075257), N-acetylcysteine (MESH:D000111), ziprasidone (MESH:C092292), benztropine (MESH:D001590), amisulpride (MESH:D000077582), GABA (MESH:D005680), Pb (MESH:D007854), Dopamine (MESH:D004298), risperidone (MESH:D018967), calcium (MESH:D002118), heavy metals (MESH:D019216), glucose (MESH:D005947), 5-HT (MESH:D012701), zuclopenthixol (MESH:D003006), histamine (MESH:D006632), Cariprazine (MESH:C533287), -Acting (-), haloperidol (MESH:D006220), paliperidone palmitate (MESH:D000068882), Clozapine (MESH:D003024), olanzapine (MESH:D000077152), Brexpiprazole (MESH:C000591922), K+ (MESH:D011188), Aripiprazole (MESH:D000068180), D3 (MESH:D002762), nicotine (MESH:D009538), valproate (MESH:D014635), corticosterone (MESH:D003345), lurasidone (MESH:D000069056)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** 1846G>A

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940323/full.md

---
Source: https://tomesphere.com/paper/PMC12940323